Hemophagocytic lymphohistiocytosis in Texas: Observations on ethnicity and race

J. Allyson Niece, Zora R. Rogers, Naveed Ahmad, Anne Marie Langevin, Kenneth L. McClain

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background. Early recognition and aggressive treatment of hemophagocytic lymphohistiocytosis (HLH) has changed a uniformly fatal disease to one 55% survive. We examined the diagnosis and treatment of pediatric patients with HLH from the three largest academic medical centers in Texas for information on modern nonstudy treatment and survival. In contrast with previously reported series, the racial and ethnic composition of Texas provided a unique opportunity to evaluate the impact of race and ethnicity on survival with HLH. Procedure. A retrospective chart review of local oncology and pathology databases identified 70 patients with HLH from 1992 to 2007. Median age was 1.8 years (range 0.1-16.5 years) and 43% were Latino. Results. We identified 70 patients with an overall survival of 67% after a median follow-up of 3 months (range 1-139 months). Twenty patients (29%) underwent stem cell transplant (SCT). Seven patients (18%) had mutations in the Perforin, Munc 13-4, or Syntaxin-11 genes, consistent with primary disease. Calculated cross-sectional prevalence of HLH in Texas from our study is 1 in 100,000 children. The effect of Latino ethnicity on survival was not statistically significant. Conclusion. HLH is a rare but potentially treatable illness with modern aggressive therapy. Though treatment is more standardized for HLH, the role of race and ethnicity as risk factors for development of disease and impact on outcome may warrant further investigation.

Original languageEnglish (US)
Pages (from-to)424-428
Number of pages5
JournalPediatric Blood and Cancer
Volume54
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Hemophagocytic Lymphohistiocytosis
Survival
Hispanic Americans
Qa-SNARE Proteins
Therapeutics
Perforin
Stem Cells
Databases
Pediatrics
Pathology
Transplants
Mutation

Keywords

  • Hemophagocytic lymphohistiocytosis
  • Histiocytosis
  • Natural killer cell

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Hemophagocytic lymphohistiocytosis in Texas : Observations on ethnicity and race. / Niece, J. Allyson; Rogers, Zora R.; Ahmad, Naveed; Langevin, Anne Marie; McClain, Kenneth L.

In: Pediatric Blood and Cancer, Vol. 54, No. 3, 03.2010, p. 424-428.

Research output: Contribution to journalArticle

Niece, J. Allyson ; Rogers, Zora R. ; Ahmad, Naveed ; Langevin, Anne Marie ; McClain, Kenneth L. / Hemophagocytic lymphohistiocytosis in Texas : Observations on ethnicity and race. In: Pediatric Blood and Cancer. 2010 ; Vol. 54, No. 3. pp. 424-428.
@article{63bb642b267c4c53975bfe4466aa0cd4,
title = "Hemophagocytic lymphohistiocytosis in Texas: Observations on ethnicity and race",
abstract = "Background. Early recognition and aggressive treatment of hemophagocytic lymphohistiocytosis (HLH) has changed a uniformly fatal disease to one 55{\%} survive. We examined the diagnosis and treatment of pediatric patients with HLH from the three largest academic medical centers in Texas for information on modern nonstudy treatment and survival. In contrast with previously reported series, the racial and ethnic composition of Texas provided a unique opportunity to evaluate the impact of race and ethnicity on survival with HLH. Procedure. A retrospective chart review of local oncology and pathology databases identified 70 patients with HLH from 1992 to 2007. Median age was 1.8 years (range 0.1-16.5 years) and 43{\%} were Latino. Results. We identified 70 patients with an overall survival of 67{\%} after a median follow-up of 3 months (range 1-139 months). Twenty patients (29{\%}) underwent stem cell transplant (SCT). Seven patients (18{\%}) had mutations in the Perforin, Munc 13-4, or Syntaxin-11 genes, consistent with primary disease. Calculated cross-sectional prevalence of HLH in Texas from our study is 1 in 100,000 children. The effect of Latino ethnicity on survival was not statistically significant. Conclusion. HLH is a rare but potentially treatable illness with modern aggressive therapy. Though treatment is more standardized for HLH, the role of race and ethnicity as risk factors for development of disease and impact on outcome may warrant further investigation.",
keywords = "Hemophagocytic lymphohistiocytosis, Histiocytosis, Natural killer cell",
author = "Niece, {J. Allyson} and Rogers, {Zora R.} and Naveed Ahmad and Langevin, {Anne Marie} and McClain, {Kenneth L.}",
year = "2010",
month = "3",
doi = "10.1002/pbc.22359",
language = "English (US)",
volume = "54",
pages = "424--428",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Hemophagocytic lymphohistiocytosis in Texas

T2 - Observations on ethnicity and race

AU - Niece, J. Allyson

AU - Rogers, Zora R.

AU - Ahmad, Naveed

AU - Langevin, Anne Marie

AU - McClain, Kenneth L.

PY - 2010/3

Y1 - 2010/3

N2 - Background. Early recognition and aggressive treatment of hemophagocytic lymphohistiocytosis (HLH) has changed a uniformly fatal disease to one 55% survive. We examined the diagnosis and treatment of pediatric patients with HLH from the three largest academic medical centers in Texas for information on modern nonstudy treatment and survival. In contrast with previously reported series, the racial and ethnic composition of Texas provided a unique opportunity to evaluate the impact of race and ethnicity on survival with HLH. Procedure. A retrospective chart review of local oncology and pathology databases identified 70 patients with HLH from 1992 to 2007. Median age was 1.8 years (range 0.1-16.5 years) and 43% were Latino. Results. We identified 70 patients with an overall survival of 67% after a median follow-up of 3 months (range 1-139 months). Twenty patients (29%) underwent stem cell transplant (SCT). Seven patients (18%) had mutations in the Perforin, Munc 13-4, or Syntaxin-11 genes, consistent with primary disease. Calculated cross-sectional prevalence of HLH in Texas from our study is 1 in 100,000 children. The effect of Latino ethnicity on survival was not statistically significant. Conclusion. HLH is a rare but potentially treatable illness with modern aggressive therapy. Though treatment is more standardized for HLH, the role of race and ethnicity as risk factors for development of disease and impact on outcome may warrant further investigation.

AB - Background. Early recognition and aggressive treatment of hemophagocytic lymphohistiocytosis (HLH) has changed a uniformly fatal disease to one 55% survive. We examined the diagnosis and treatment of pediatric patients with HLH from the three largest academic medical centers in Texas for information on modern nonstudy treatment and survival. In contrast with previously reported series, the racial and ethnic composition of Texas provided a unique opportunity to evaluate the impact of race and ethnicity on survival with HLH. Procedure. A retrospective chart review of local oncology and pathology databases identified 70 patients with HLH from 1992 to 2007. Median age was 1.8 years (range 0.1-16.5 years) and 43% were Latino. Results. We identified 70 patients with an overall survival of 67% after a median follow-up of 3 months (range 1-139 months). Twenty patients (29%) underwent stem cell transplant (SCT). Seven patients (18%) had mutations in the Perforin, Munc 13-4, or Syntaxin-11 genes, consistent with primary disease. Calculated cross-sectional prevalence of HLH in Texas from our study is 1 in 100,000 children. The effect of Latino ethnicity on survival was not statistically significant. Conclusion. HLH is a rare but potentially treatable illness with modern aggressive therapy. Though treatment is more standardized for HLH, the role of race and ethnicity as risk factors for development of disease and impact on outcome may warrant further investigation.

KW - Hemophagocytic lymphohistiocytosis

KW - Histiocytosis

KW - Natural killer cell

UR - http://www.scopus.com/inward/record.url?scp=76749084228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76749084228&partnerID=8YFLogxK

U2 - 10.1002/pbc.22359

DO - 10.1002/pbc.22359

M3 - Article

C2 - 19953651

AN - SCOPUS:76749084228

VL - 54

SP - 424

EP - 428

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -